Premium
Ciprofloxacin: Drug of choice in the treatment of malignant external otitis (MEO)
Author(s) -
Levenson Mark J.,
Parisier Simon C.,
Dolitsky Jay,
Bindra Gurpaul
Publication year - 1991
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-199108000-00004
Subject(s) - ciprofloxacin , medicine , otitis , osteomyelitis , dose , skull , surgery , quinolone , radiology , antibiotics , microbiology and biotechnology , biology
Ciprofloxacin, a fluorinated quinolone with high efficacy against Pseudomonas aeruginosa , was used in the treatment of 10 consecutive patients with malignant external otitis. All patients had skull base osteomyelitis documented by nuclear and computed tomography (CT) scans. Dosages of 1.5 g of ciprofloxacin daily were used for a mean average of 10 weeks. All patients were considered cured with a minimum follow‐up of 18 months after completion of therapy. A new classification of malignant external otitis (MEO) is presented.